GSK plans 121 job cuts at Irish plant; Novartis wins suit over Zometa;

 @FiercePharma: Pharma cuts 6,000+ jobs in Sept. Article | Follow @FiercePharma

> GlaxoSmithKline has completed its review of a manufacturing facility in Ireland and concluded that it will have to shed 121 staff from its 450-plus workforce. Report

> A New Jersey jury ruled that Novartis provided adequate warnings about the risk of its bone-strengthening medicines, rejecting a lawsuit by a woman who claimed the drugs destroyed her jaw. Report

> New details are emerging about shortcomings at Gilead Sciences' San Dimas, California, plant as the FDA posted its warning letter about those problems. Report

> U.S. health regulators plan to spend millions of dollars to step up their scientific prowess in a move that officials say will help quickly get new treatments to patients and protect the public against possible health threats. Report

> GeneScience Pharmaceutical, a Chinese drug company, and its chief executive have agreed to plead guilty today to charges of illegally distributing human growth hormones in the U.S. Report

> Swedish contract development and manufacturing services company Recipharm has agreed to buy a facility in Parets del Valles, Spain, from Abbott Laboratories for an undisclosed sum. Report

> With last week's announcement by the FDA that it was ordering unapproved colchicine products off the market, the year-old debate over the agency's handling of the popular gout treatment has flared anew. Report

>GlaxoSmithKline has retained an 18 percent minority equity stake in spin-off biotechnology group Convergence Pharmaceuticals, which was officially launched yesterday with financing of $35.4 million from a syndicate of leading European and U.S. life science investors. Report

Biotech News

 @FierceBiotech: Investors buck as Crucell backs J&J's $2.4B bid. Article | Follow @FierceBiotech

 @JohnCFierce: Biogen Idec's new chief is planning a big revamp of R&D, with more collaborations involving small biotechs. Article |  Follow @JohnCFierce

> Novartis, Venter team on faster vax development. Report

> Pirfenidone will make or break InterMune. Article

> With $1.25B bond sale, Celgene eyes deals. Story

> Targacept ADHD candidate shows disappointing results in Ph2 trial. Item

Manufacturing News

> RFID system targets drug fakes in Nigeria. Report

> Caraco leads ops-margin minimizers. News

> Faulty sieve likely shed metal, driving pill recall. Article

> For J&J, Crucell ops quality an acquisition bonus. Story

> Gilead warning cites animated operator. News

Vaccines News

> Celldex vax extends life of brain tumor patients in study. Story

> Offit: Children's vaccines are vital. Report

> Combo anthrax/smallpox vax beats anthrax vax alone. Article

And Finally... A strain of a drug-resistant skin disease that has afflicted sports teams, prisons and military units is now proving a persistent pest among lobstermen and their families on a Maine island. Report

Suggested Articles

AZ's tremelimumab has so far suffered a host of clinical failures. But new trial results show the company might be able to use the drug in a new way.

Roche may have just grabbed the first FDA nod for a checkpoint med in previously untreated liver cancer, but Merck is hoping it won’t be far behind.

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.